Key facts
- It has raised $3.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, BSK Investment, Daekyo Investment, Firstgate (South Korea) — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Elphis Cell Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Elphis Cell Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elphis Cell Therapeutics
Developer of personalized cell therapies designed for vascular diseases. The company offers disease treatment utilizing complex stem cells that combine vascular endothelial progenitor cells for regenerating blood vessels and MSC, enabling healthcare professionals to address patients' symptomatic relief, including vascular bypass surgery, stents, and balloon angioplasty for mild cases.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 15
- Website
- elphiscellrx.com/
- Ownership
- Privately Held (backing)
Elphis Cell Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elphis Cell Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elphis Cell Therapeutics in its N-PORT filings yet. We sweep new filings monthly.